These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 4005126)

  • 21. The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration.
    Gregg MR; Jack DB; Smith SR; Kendall MJ
    J Clin Pharm Ther; 1987 Apr; 12(2):91-9. PubMed ID: 3584272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of metoprolol OROS with antenolol in the treatment of effort angina pectoris: a randomized double-blind study.
    Floris B; Paoletti G; Pelizza L; Bertulla A; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1991 Apr; 29(4):139-43. PubMed ID: 1906434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
    Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of drug absorption from the gastrointestinal tract of man. III. Metoprolol in the colon.
    Godbillon J; Evard D; Vidon N; Duval M; Schoeller JP; Bernier JJ; Hirtz J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):113S-118S. PubMed ID: 4005112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of the IntelliCap® system as a tool to evaluate extended release profiles in human GI tract using metoprolol as model drug.
    Söderlind E; Abrahamsson B; Erlandsson F; Wanke C; Iordanov V; von Corswant C
    J Control Release; 2015 Nov; 217():300-7. PubMed ID: 26385166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controlled release metoprolol. Clinical pharmacokinetic and therapeutic implications.
    Kendall MJ; Maxwell SR; Sandberg A; Westergren G
    Clin Pharmacokinet; 1991 Nov; 21(5):319-30. PubMed ID: 1773547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of OROS metoprolol in mild and moderately severe essential hypertension].
    Hradec J; Král J; Petrásek J
    Cas Lek Cesk; 1990 Jun; 129(23):709-13. PubMed ID: 2393874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Preparation of transdermal drug delivery system of felodipine-metoprolol and its bioavailability in rabbits].
    Wang WG; Yun LH; Wang R; Fu GY; Liu ZY
    Yao Xue Xue Bao; 2007 Nov; 42(11):1206-14. PubMed ID: 18300480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.
    Theeuwes F; Swanson DR; Guittard G; Ayer A; Khanna S
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):69S-76S. PubMed ID: 4005132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility and functionality of OROS melatonin in healthy subjects.
    Shah J; Langmuir V; Gupta SK
    J Clin Pharmacol; 1999 Jun; 39(6):606-12. PubMed ID: 10354964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
    Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers.
    Deroubaix X; Lins RL; Lens S; Demblon C; Jeanbaptiste B; Poelaert D; Stockis A
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):61-70. PubMed ID: 8929748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of AST-120 on the single-dose pharmacokinetics of metoprolol extended-release tablets in healthy subjects.
    Inoue S; Shimizu M; Arita K; Akimoto K
    Drug Metabol Drug Interact; 2014; 29(2):115-21. PubMed ID: 24643911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development and pharmacokinetic study of metoprolol tartrate controlled-release tablet remaining-floating in stomach].
    Li SL; Tu XD; Mao FF
    Yao Xue Xue Bao; 1989; 24(5):381-6. PubMed ID: 2609974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers.
    Johnsson G; Jordö L; Lundborg P; Regårdh CG; Rönn O
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):292-7. PubMed ID: 7000717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK; Sathyan G
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of sustained-release tablets of metoprolol in Chinese.
    Diao Y; Li L
    Zhongguo Yao Li Xue Bao; 1993 May; 14(3):232-4. PubMed ID: 8237398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and pharmacokinetics of Logimax, a new extended-release combination tablet of felodipine and metoprolol.
    Abrahamsson B; Edgar B; Lidman K; Wingstrand K
    Blood Press Suppl; 1993; 1():10-5. PubMed ID: 8173686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.
    Davis SS; Washington N; Parr GD; Short AH; John VA; Lloyd P; Walker SM
    Br J Clin Pharmacol; 1988 Oct; 26(4):435-43. PubMed ID: 3056482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.